Bridge Pharmaceuticals Names Vincent S. Lagrotteria as Vice President of Global Sales and Marketing.

GAITHERSBURG, Md. -- Bridge Pharmaceuticals, Inc. (Bridge), a contract research organization (CRO) providing GLP-compliant preclinical drug development services in the US and China, announced the appointment of Vincent S. Lagrotteria to Vice President of Global Sales and Marketing, effective immediately. Mr. Lagrotteria brings to Bridge more than 20 years of healthcare sales experience in a wide variety of leadership positions.

"When we saw the breadth of Vinny's experience and his exceptional sales achievements, we were eager to have him join us," said Bridge CEO Tom Oakley. "We are delighted to welcome him aboard."

"I am excited to join a company truly bridging East and West," said Mr. Lagrotteria. "Only Bridge offers preclinical toxicology services in the US and China fully compliant to international GLP standards. But that just scratches the surface. Bridge's unique combination of comprehensive general toxicology and hard-to-find specialty services along with years of scientific experience creates unparalleled advantages for accelerating pharmaceutical development. My goal is getting our full story in front of the customers."

Prior to Bridge, Mr. Lagrotteria was Vice President, Global Sales and Marketing for Bilcare, a Phoenixville, PA provider of drug development services in the US, India, and the UK. Earlier, he was Vice President, Global Business Development, for Charles River Laboratories of Cary, NC and Senior Vice President of Sales, Marketing and Strategic Initiatives, for Medifacts International of Rockville, MD. His bachelor's degree in business is from Towson State University. He earned his MBA and election to marketing honors society Mu Kappa Tau at Loyola College of Maryland.

Bridge Overview

Bridge Pharmaceuticals, Inc. is one of the first preclinical contract research organization (CRO) to provide US-level drug development services in both Asia and the US. Bridge is headquartered in the United States with laboratories in Gaithersburg, Maryland and Beijing, China. Bridge focuses on providing cost-effective, high-quality FDA compliant drug development services for pharmaceutical, biotech and government clients. Bridge's current capabilities in preclinical drug development include GLP compliant toxicology, safety pharmacology, pathology and bioanalytical services. For more information, visit http://www.bridgecro.com.